<div id="readability-page-1"><p>Russell Investments Group Ltd. increased its position in  Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 444.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,549 shares of the company's stock after purchasing an additional 33,922 shares during the quarter. Russell Investments Group Ltd. owned 0.06% of Arvinas worth $292,000 as of its most recent filing with the Securities and Exchange Commission.</p><ul><li> 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023</li></ul><p>Other institutional investors and hedge funds have also made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of  Arvinas in the fourth quarter valued at $28,000.  GAMMA Investing LLC boosted its stake in shares of  Arvinas by 11,283.8% in the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock valued at $300,000 after purchasing an additional 4,175 shares during the period.  CWM LLC boosted its stake in shares of  Arvinas by 2,317.5% in the first quarter. CWM LLC now owns 7,615 shares of the company's stock valued at $53,000 after purchasing an additional 7,300 shares during the period.  Aigen Investment Management LP purchased a new position in shares of  Arvinas in the first quarter valued at $77,000.  Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of  Arvinas in the first quarter valued at $80,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several research analysts have recently weighed in on ARVN shares. Leerink Partnrs downgraded shares of Arvinas from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, June 1st. UBS Group cut their price target on shares of Arvinas from $74.00 to $21.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, May 15th. Leerink Partners  reaffirmed a &#34;market perform&#34; rating and issued a $9.00 price target (down from $10.00) on shares of Arvinas in a report on Monday, June 2nd. Morgan Stanley cut their price target on shares of Arvinas from $12.00 to $11.00 and set an &#34;equal weight&#34; rating on the stock in a report on Friday, May 9th. Finally, Wells Fargo &amp; Company cut their price target on shares of Arvinas from $19.00 to $16.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, August 7th. Twelve analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $19.76.</p><p><b>Read Our Latest Report on ARVN</b></p><h2>Insider Buying and Selling at Arvinas</h2><p>In other Arvinas news, CFO Andrew Saik sold 5,700 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total transaction of $43,377.00. Following the sale, the chief financial officer directly owned 164,401 shares of the company's stock, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Company insiders own  4.73% of the company's stock. </p><h2>Arvinas Stock Performance</h2><p>Shares of NASDAQ:ARVN opened at $7.73 on Tuesday. The stock has a market capitalization of $567.54 million, a price-to-earnings ratio of -7.65 and a beta of 2.38. Arvinas, Inc. has a 1-year low of $5.90 and a 1-year high of $29.61. The company's fifty day moving average is $7.49 and its two-hundred day moving average is $8.64. </p><p>Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.03. The company had revenue of $22.40 million for the quarter, compared to analysts' expectations of $34.42 million. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The firm's revenue was down 70.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.49) earnings per share.  Sell-side analysts expect that  Arvinas, Inc. will post -3.81 EPS for the current fiscal year. </p><h2>Arvinas Company Profile</h2> (Free Report)<p>Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Arvinas</li><li>Bank Stocks - Best Bank Stocks to Invest In</li><li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li><li>How to Plot Fibonacci Price Inflection Levels </li><li>3 Tariff-Proof Retailers Making New All-time Highs</li><li>How to Start Investing in Real Estate</li><li>With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report</li></ul><p><strong>Want to see what other hedge funds are holding ARVN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arvinas Right Now?</h2><p>Before you consider Arvinas, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.</p><p>While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARVN

<p>Russell Investments Group Ltd. significantly increased its stake in Arvinas, Inc. by 444.8% in Q1, owning 41,549 shares valued at $292,000. Other institutional investors also raised their positions. Analysts have mixed ratings on Arvinas, with price targets ranging from $9.00 to $21.00. The stock opened at $7.73, with a market cap of $567.54 million. Arvinas reported a quarterly loss of $0.84 EPS, with revenue down 70.7% year-over-year. The company focuses on developing therapies to degrade disease-causing proteins.</p>

Russell Investments Group Ltd. Increases Stock Position in Arvinas, Inc. $ARVN